

PRESS RELEASE

CordLife first to present the standard in cord blood banking

- A proven quality and technology pioneer, CordLife is once again the first and only family bank in Asia to offer superior automated cord blood processing using Sepax.
- Sepax is the world's most recognised and widely adopted automated cord blood processing technology which performs smooth and precise cell separation.
- The first baby in Singapore, as well as Asia, to benefit from Sepax is Alina Lee's newborn son

 signalling a milestone in cord blood processing in Asia.
- Sepax is U.S. FDA cleared and accredited by numerous health ministries worldwide including Japan, the European Union, Canada and Australia, to name a few. Sepax is also known for its Swiss made accuracy.

SINGAPORE, **15 December 2008** – Aaron Chong became Asia's first baby to have his cord blood processed using *Sepax*, a superior automated processing system available only at CordLife. An early Christmas gift of a lifetime for Aaron was unwrapped on 11 November 2008 when his mother Alina Lee had his cord blood processed by CordLife using *Sepax*, an internationally recognised and widely adopted automated system for stem cell separation. CordLife is the first and only family bank in Asia to achieve this significant milestone in cord blood processing.

"In line with our quality and technology pioneer status, we are pleased to introduce the world's most recognised and widely adopted automated cord blood processing technology firstly to Singapore, followed by our other facilities in Asia. Stem cell isolation is a critical step in cord blood banking; which is why we have invested in *Sepax* after much research and trials. It is a safe and sterile technology that has been proven to harvest the highest number of stem cells, compared to other processing methods in the industry. If ever needed, a higher number of stem cells will enhance the success of the transplant," said Steven Fang, Group CEO of CordLife; a homegrown cord blood bank that has developed into the largest network of cord blood banks in Asia Pacific.

Sepax is U.S. FDA cleared and accredited by numerous health ministries worldwide including Japan, the European Union, Canada and Australia, to name a few. Known for its Swiss made accuracy, Sepax is compliant with both AABB (formerly American Association of Blood Banks) and FACT Netcord, recognised global standards for cord blood banking. The preferred choice among 70% of Netcord banks, Sepax has processed over 400,000 cord blood units in 40 countries and thousands have been used in transplants globally.

"After learning about CordLife's AABB accreditation and the benefits of their new technological advancement, I knew it is the best gift for my child which he will still appreciate 21 years later. It is a nice surprise to be the first, and I also feel good because it maximised our investment," said Ms Lee whom also banked her first born daughter's cord blood.



About CordLife

CordLife is a regional cord blood bank that operates the world's largest network of cord blood banks with full processing and cryopreservation storage facilities in Singapore, Australia, Hong Kong, Indonesia and India as well as marketing operations in Macau, Philippines and Thailand. The first cord blood bank to be set up in Singapore, and among the first in Asia, CordLife's state of the art facility is the first and only private cord blood bank in Southeast Asia to be accredited by AABB and is also licensed by the Ministry of Health, Singapore. CordLife is listed on the Australian Stock Exchange, under the symbol, CBB. For more information, please visit www.cordlife.com.

About Sepax

Specially invented nine years ago to ensure smooth and precise cell separation without operator intervention – *Sepax* significantly reduces risk of cross contamination as well as operator error. The processing step is one of the most important and involves separating the stem cells from the other components, such as red blood cells and plasma. During this separation procedure, the cord blood is spun to create a centrifugal force that separates the components based on their density. Previously, this procedure was performed manually using a transfer set, syringes and a centrifuge. For the last few years, there has been a move in both public and private banks to standardise this process through automation and today a large majority of the top banks around the world use Sepax as the reference cord blood processing technology. For more information, please visit www.processedbysepax.com.

About Biosafe SA

Biosafe is the industry standard in automated adult stem cell processing and a leader in the expansive field of regenerative medicine. With the proprietary Sepax technology, Biosafe offers the only fully automated solution in adult stem cell processing and has become the system of reference for the majority of leading cord blood banks worldwide. Biosafe is a U.S. FDA registered medical device manufacturer as well as an ISO 9001:2000 and ISO 13485:2003 certified company. For more information, please visit www.processedbysepax.com.

For more information, please contact:

Susan Kheng CordLife Pte Ltd Tel: (65) 6238 0808

Tel: (66) 6266 6666

Email: susan.kheng@cordlife.com

Steven Fang CordLife Pte Ltd Tel: (65) 6238 0808

Email: sfang@cordlife.com